At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Eluxadolinedrug
Likely dose
Eluxadoline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)
In Brief
A Phase 4 clinical trial evaluating Eluxadoline for Irritable Bowel Syndrome With Diarrhea. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome With Diarrhea
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartFeb 2018
Primary CompletionApr 2020
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartFeb 23, 2018
Primary CompletionApr 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.4 years ago
Interventions
Eluxadolinedrug
Eluxadoline 100 mg oral tablets BID with food.